Zepbound vs Mounjaro: Same Molecule, Different Names and Indications

You're comparing two tabs. One pharmacy site lists Zepbound, and your prescription says Mounjaro. So are these two different drugs? Zepbound vs Mounjaro can look like a rivalry, but both brands share the same active ingredient, tirzepatide. What changes is the brand name and, in some countries, the approved use. This guide shows you how to read a label and sort out the names yourself, and it ends with questions to bring to your next appointment.

One Molecule, Two Brand Names

Tirzepatide is a single active ingredient. It acts on two hormone receptors, GIP and GLP-1, which makes it a dual agonist. Eli Lilly is listed as the applicant for both Mounjaro and Zepbound in FDA's Drugs@FDA database. That part doesn't change, whichever box is in your hand.

Brand names are trademarks, and trademarks are registered market by market. A company checks that a name is available in each country and files for it there. One molecule can therefore wear different names in different places. Picking a name is a commercial and legal decision. It doesn't change the drug inside.

Here's the US timeline. FDA approved Mounjaro for type 2 diabetes in May 2022. In November 2023, it approved Zepbound for chronic weight management. Same molecule, two approvals, two names, and two separate labels.

Why the Name and the Indication Split

Each regulator reviews its own dossier. FDA covers the US, EMA covers the European Union, MHRA covers the UK, ANVISA covers Brazil, and Health Canada covers Canada. Each one decides which brand name it accepts and which indication goes on the label.

Companies don't file everywhere at once, and they don't always ask for the same use. A diabetes approval might come first, with weight management filed later or not filed at all in a given market. A country may approve weight management later than the US, or not under that brand. The same name can mean different things across borders.

You can check the record yourself. Search Drugs@FDA for US entries and DailyMed for the current US label text. For Europe, EMA's public EPAR page for Mounjaro lists the approved indication and the approval date. In Brazil, ANVISA's medicine consultation portal shows registered products. If you want a wider view of how names differ between markets, TirzeBlog's coverage of brand names across markets is a useful place to start, but the regulator's record is the final word.

What the Indications Actually Cover

In most markets, Mounjaro is approved for glycemic control in adults with type 2 diabetes. Zepbound's US label covers chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition. Those two descriptions point to different patients, even though the molecule is identical.

In December 2024, FDA also approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. That's one condition in one group, based on the studies behind the label. It doesn't mean everyone with sleep apnea will benefit, and it doesn't replace an evaluation by a sleep specialist.

Prescribers sometimes use approved medicines for purposes the label doesn't mention. That's a clinical decision, made after your doctor reviews your history and the available evidence. It isn't a way for buyers to get a different label. If your prescription doesn't match the indication you read, ask your prescriber directly.

Copy the indication wording from the current US Zepbound label and the current Mounjaro label for your country. Note the revision date on each one, because labels change when new indications are added.

How to Read Your Own Label

Start with the active ingredient line. If it says tirzepatide, the molecule matches the brand on the box. Then read the indication section. It lists the approved population, including age, diagnosis, and any weight threshold, along with the stated use. A diabetes label and a weight-management label can name the same molecule and still describe very different people.

Next, find the regulator, the product name, and the label version or date printed on the leaflet or carton. That date tells you whether you're holding the current version. Pharmacies sometimes hand out older leaflets, so check it.

Compare the pen strength and dose steps against both the box and your prescription. Doses are usually listed in milligrams per pen. US labels for both brands commonly show pens from 2.5 mg to 15 mg, but the exact steps come from the current label for your market, so confirm them there. If a leaflet feels dense, the label-reading steps at TirzeBlog can help you find each field faster.

Compounded Products, Imports, and Mix-Ups

From roughly 2022 until FDA declared the shortage resolved in 2024, compounded tirzepatide was sold widely in the US. Compounded drugs aren't FDA-approved. FDA doesn't review them for potency, purity, and sterility the way it reviews approved products. That gap matters when you inject something once a week.

Online sellers add their own problems. Some use product names you won't recognize, skip the prescription, or ship without clear storage instructions. A wrong dose, contamination, or a package with no label to check are all real possibilities. If a box lacks a lot number, a regulator's name, or a leaflet, you can't verify what's inside.

Insurance and pharmacy billing follow the approved brand and indication. When the product in your hands doesn't match your prescription, a claim can be rejected. Pens, vials, and brands that list doses differently also cause mix-ups. Ask your prescriber or pharmacist to confirm the dose before your first injection and whenever the product changes.

Questions to Bring to Your Doctor or Pharmacist

Bring these to your next appointment or pickup. The four questions below follow the same checks covered on TirzeBlog, and you can copy them into a note on your phone if paper isn't handy.

• Which brand and which indication appear on my prescription, and does that match the label in my country?
• Is this product approved where I live, or is it compounded or imported?
• Will my insurance or pharmacy cover the exact brand I was prescribed?
• What is my starting dose and pen strength, and how do I confirm it against the box?

Three ideas carry most of this. Tirzepatide is the same molecule whether it's sold as Mounjaro or Zepbound. Each regulator sets the brand name and indication for its own market. And your label and prescription are where you check that everything lines up. Approval status varies by country, so a product approved in one place may not be approved in yours.

Treatment decisions belong to your prescriber, who knows your health history. Tirzepatide can help some adults with weight management or blood sugar, but no label guarantees results, and no one can promise a cure. Start with the questions above and let your prescriber fill in the rest.

FAQ

Is Zepbound the same as Mounjaro?

They contain the same active ingredient, tirzepatide. The brand name and the approved use can differ, so check the label issued in your own country.

Can I use Mounjaro for weight loss?

In most markets, Mounjaro is approved for type 2 diabetes. A prescriber can sometimes use approved medicines for other purposes, but that's a clinical decision. Talk with your prescriber about what fits your situation.

Why does my pharmacy show a different name than my prescription?

The pharmacy may be dispensing a different brand with the same molecule, or the prescription may use another name. Ask the pharmacist to confirm the brand, strength, and indication on the label.

Is compounded tirzepatide approved by the FDA?

No. Compounded products aren't FDA-approved, and they aren't reviewed for potency and sterility the way approved medicines are. Buying from an unverified source adds more risk.

Sources

• FDA Drugs@FDA database
• FDA Drug Shortages Database
• FDA Human Drug Compounding
• DailyMed (U.S. National Library of Medicine)
• EMA EPAR: Mounjaro (tirzepatide)
• ANVISA Consulta de Medicamentos
• MHRA Products Database
• Health Canada Drug Product Database